The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of
direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with
Child B liver cirrhosis (LC). The primary objective of this study is to verify the ability of
apixaban and edoxaban to decrease in vivo thrombin generation in LC patients.
Participants will be randomly assigned to either apixaban (Eliquis®) or edoxaban (Lixiana®)
at a therapeutic dosage for 7 consecutive days.
The results of this investigation will contribute to designing a prospective multicentre
interventional study to investigate the efficacy of DOAC for primary prevention of portal
vein thrombosis in LC patients at high thrombotic risk.